Main Article Content
Dying undiagnosed, ovarian tumours, ABUTH, challenges, management, ovarian cancer, resource poor setting
Background: Ovarian cancer is the second most prevalent but most lethal gynaecologic malignancy in our institution. This study aimed at determining the rate of non-diagnosis in suspected lesions and reviewing the management challenges of ovarian tumours highly suspicious for malignancy in our hospital.
Methodology: A three-year retrospective review of patients’ records from the ward, clinic, theatre, and histopathology laboratory was carried out. Cases with high indices of suspicion for ovarian cancer (ovarian tumour with malignant radiologic features with any of ascites, pleural effusion, cachexia, anaemia, or evidence of metastasis) were included. In-depth interviews were carried out with a consultant from each speciality of Radiology, Radio-oncology, Pathology and Gynaecologic oncology at the gynaecologic oncology multidisciplinary team meeting.
Results: 122 cases of highly suspicious ovarian malignancies were seen with a mean age of 40.6 years. Of these, 28 (23%) had surgery and 77% had no histological diagnosis. Of those that had surgery, 13 (46.4%) had upfront surgery and 15 (53.6%) neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). Only two cases had documented complete (R0) debulking. Among those that had upfront surgery, one case (7.7%) was an ovarian fibroid and one (7.7%) was a fibrosarcoma while two cases (15.4%) were borderline ovarian tumours. In three cases, chemotherapy was commenced based on malignant cells on ascitic or pleural fluid cytology. Of all the malignant cases, epithelial carcinomas were the most common accounting for 48%.
Conclusion: Most patients with tumours highly suspicious of ovarian cancers did not get a histologic diagnosis and probably died undiagnosed. Management of ovarian cancer remains a challenge despite advances in surgical and chemotherapeutic options. Health insurance for all, infrastructure development and training of all disciplines involved is recommended.
2. Renganathan R, Renganathan P, Palak BP, Smita M, Kasi V, Anuradha C et al. Imaging Recommendations for Diagnosis, Staging, and Management of Ovarian and Fallopian Tube Cancers. Ind J Med PaediatrOncol 2023; 44:100–109.
3. Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2021;397 (10290):2182–2193
4. Andreotti RF, Timmerman D, Strachowski LM, et al. O-RADS US risk stratification and management system: a consensus guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee. Radiology 2020;294(01):168–185.
5. Wang Y, Sundfeldt K, Mateoiu C, Shih IeM, Kurman RJ, Schaefer J, Silliman N, Kinde I, Springer S, Foote M, Kristjansdottir B, James N, Kinzler KW, Papadopoulos N, Diaz LA, Vogelstein B. Diagnostic potential of tumor DNA from ovarian cyst fluid. Elife. 2016 Jul 15;5: e15175
6. Hewitt MJ, Anderson K, Hall GD, Weston M, Hutson R, Wilkinson N, Perren TJ, Lane G, Spencer JA. Women with peritoneal carcinomatosis of unknown origin: Efficacy of image-guided biopsy to determine site-specific diagnosis. BJOG. 2007;114(1):46.
7. NCCN Clinical Practice Guidelines in Oncology Epithelial ovarian cancer (including fallopian tube cancer and primary peritoneal cancer). Version 1.2022. Accessed November 09, 2022, at: https:// www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
8. Mehdi G, Maheshwari V, Afzal S, et al. Image-guided fine-needle aspiration cytology of ovarian tumors: An assessment of diagnostic efficacy. J Cytol 2010; 27:91.
9. Daly MB, Pal T, Berry MP, et al; Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J NatlComprCancNetw 2021;19(01):77–102. Doi: 10.6004/jnccn.2021.0001
10. Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J ClinOncol. 2020;38(11):1222. Epub 2020 Jan 27.
11. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29. PMID: 29809280; PMCID: PMC6621554.
12. Boyarskikh UA, Gulyaeva LF, Avdalyan AM, Kechin AA, Khrapov EA, Lazareva DG, Kushlinskii NE, Melkonyan A, Arakelyan A, Filipenko ML. Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer. Front Oncol. 2020 Jul 16;10:1103. doi: 10.3389/fonc.2020.01103.
13. Alsop K, Fereday S, Meldrum C, de Fazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J ClinOncol. (2012) 30:2654–63. 10.1200/JCO.2011.39.8545
14. Obijiaka C. Only six percent of Nigerians have health insurance, says care providers. Guardian newspaper online. June 22, 2023 4:35amhttps://guardian.ng/news/only-six-per-cent-of-nigerians have-health-insurance-say-care-providers/
15. Fatunmole M. Key issues in Nigeria’s new National Health Insurance Authority Act. International Centre for Investigative Reporting. June 20, 2022https://www.icirnigeria.org/key-issues-in nigerians-new-national-health-insurance-authority-act/
16. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2018, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2018/, based on November 2020 SEER data submission, posted to the SEER website, April 2021
17. Zayyan MS, Ahmed SA, Oguntayo AO, Kolawole AO, Olasinde TA. Epidemiology of ovarian cancers in Zaria, Northern Nigeria: A 10-year study. Int J Womens Health. 2017. doi:10.2147/IJWH.S130340
18. Iyoke CA, Ugwu GO, Ezugwu EC, Onah N, Ugwu O, Okafor O. Incidence, pattern, and management of ovarian cancer at a tertiary medical center in Enugu, Southeast Nigeria. Ann Med Health Sci Res 2013;3:417-21.
19. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287. doi:10.2147/IJWH.S197604.
20. Irish Cancer Society. How common is Ovarian cancer? Cancer. ie. https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html. Published 2016. Accessed April 7, 2020.
21. Edmondson RJ, Monaghan JM. The epidemiology of ovarian cancer. Int J Gynecol Cancer. 2001;11(6):423-429
22. George SHL, Omotoso A, Pinto A, Mustapha A, Sanchez-Covarrubias AP et al. An Assessment of Ovarian Cancer Histotypes Across the African Diaspora. Front. Oncol.2021 11:732443. doi: 10.3389/fonc.2021.732443
23. DeSantis, C. E., Siegel, R. L., Sauer, A. G., Miller, K. D., Fedewa, S. A., Alcaraz, K. I. & Jemal, A. Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin, doi:10.3322/caac.21340 (2016).
24. Connolly JL, Schnitt SJ, Wang HH, Longtine JA, Dvorak A, Dvorak HF. Role of the Surgical Pathologist in the Diagnosis and Management of the Cancer Patient. 2003.
25. Ibrahim HM, Ijaiya MA. Pattern of Gynaecological Malignancies at the University of Ilorin Teaching Hospital, Ilorin, Nigeria. J ObstetGynaecol (2013) 33(2):194–6. doi: 10.3109/01443615.2012.738717
26. Forae GD, Aligbe JU. Ovarian TumorsAmong Nigerian Females: A Private Practice Experience in Benin-City, Nigeria. AdvBioMed Res (2016) 5:61. doi: 10.4103/2277-9175.179183
27. Kazeem Y. Nigeria has become the poverty capital of the world. Quartz. June 25,
28. Olafusi E. Cancer patients to save 50% treatment cost with FG’s ‘Chemo programme.’ The Cable online. October 30, 2019 at 11:09pm https://www.thecable.ng/fg-launches-chemotherapy programme-to-cut-cancer-treatment-cost-by-50.
29. Osigbesan, O. "Medical Brain Drain and its Effect on the Nigerian Healthcare Sector" (2021). Walden Dissertations and Doctoral Studies. 10828. https://scholarworks.waldenu.edu/dissertations/10828
30. Noll F, Adams T, Cohen R, Soerjomataram I, Reid F. Building opportunities to improve quality of life for women with ovarian cancer in low- and middle-income countries: Every Woman Study. Int J Gynecol Cancer. 2022 Aug 1;32(8):1080-1081. doi: 10.1136/ijgc-2022-003449. PMID: 35314459.
31. Mathieu KB, Bedi DG, Thrower SL, Qayyum A, Bast RC. Screening for ovarian cancer: imaging challenges and opportunities for improvement. Ultrasound Obstet Gynecol. 2018;51(3):293-303. doi:10.1002/uog.17557
32. Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, Hartge P, Fagerstrom RM, Ragard LR, Chia D, Izmirlian G, Fouad M, Johnson CC, Gohagan JK, Team PP, PLCO Project Team Ovarian cancer screening in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. American Journal of Obstetrics and Gynecology. 2005;193:1630–1639. doi: 10.1016/j.ajog.2005.05.005.
33. Salpingectomy as a Means to Reduce Ovarian Cancer Risk. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417454/. Accessed April 8, 2020.
34. Morhason-Bello I. O., Odedina F., Rebbeck T. R., et al. Challenges and opportunities in cancer control in Africa: a perspective from the African Organization for Research and Training in Cancer. The Lancet Oncology. 2013;14(4):e142–e151
35. Adesina A., Chumba D., Nelson A. M., et al. Improvement of pathology in sub-Saharan Africa. The Lancet Oncology. 2013;14(4):e152–e157.